Quantcast

Latest Steven Rosenberg Stories

2014-07-01 11:10:06

American Association for Cancer Research A new approach demonstrated that the recognition of unique cancer mutations appeared to be responsible for complete cancer regressions in two metastatic melanoma patients treated with a type of immunotherapy called adoptive T-cell therapy. This new approach may help develop more effective cancer immunotherapies, according to a study published in Clinical Cancer Research, a journal of the American Association for Cancer Research. "This study...

2014-03-05 10:57:36

An experimental drug aimed at restoring the immune system's ability to spot and attack cancer halted cancer progression or shrank tumors in patients with advanced melanoma, according to a multisite, early-phase clinical trial at Johns Hopkins Kimmel Cancer Center and 11 other institutions. All patients had experienced disease progression despite prior systemic therapies, and most had received two or more prior treatments. Patients who showed responses to the drug, nivolumab (anti-PD-1;...

2012-03-06 06:21:30

(Ivanhoe Newswire)-- Those suffering from Melanoma may have new hope. A recent study shows that a patient's own cells may reduce advanced melanoma and send the cancer into remission. Cassian Yee, M.D., a member of the Clinical Research Division of Fred Hutchinson Cancer Research Center, had a goal to find the ideal cellular environment in which to infuse 15 billion to 20 billion cancer-fighting CD8+ T cells so that they remain for as long as possible in the body to battle the tumors. The...

2012-02-07 21:09:36

New therapy combination prolongs survival in dogs and furthers research for human trials A new immunotherapy for companion dogs with advanced-stage non-Hodgkin lymphoma (NHL) has been shown to improve survival while maintaining quality of life, according to a study published in the journal Scientific Reports. The study resulted from a collaboration between The University of Texas MD Anderson Children´s Cancer Hospital in Houston and Texas A&M University College of Veterinary...

2011-08-10 06:00:00

LOS ANGELES, Aug. 10, 2011 /PRNewswire/ -- Genesis Biopharma, Inc. (OTC/BB: GNBP), a biotechnology company developing targeted cancer immunotherapies, today announced it has signed a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI). Under the terms of the five-year cooperative research and development agreement, Genesis Biopharma will work with Steven A. Rosenberg, M.D., Ph.D., the NCI Surgery Branch Chief, to develop adoptive cell...

2011-02-01 12:29:33

Researchers have found that a novel form of personalized therapy that genetically engineers a patient's own anti-tumor immune cells to fight tumors could treat metastatic melanoma and metastatic synovial cell sarcoma, representing a potentially new therapeutic approach against these and other cancers. The technique, called adoptive immunotherapy, works with the body's immune system to fight cancer. Immune cells, called T lymphocytes, are removed, modified, expanded in large numbers, and given...

2010-11-25 08:16:41

(Ivanhoe Newswire) -- Complete remission of cancer is what many of the more than 68,000 patients who will be diagnosed with melanoma this year would love to hear.A potent anti-tumor gene introduced into mice with metastatic melanoma has resulted in permanent immune reconfiguration and produced a complete remission of their cancer. Indiana University School of Medicine researchers used a modified lentivirus to introduce a potent anti-melanoma T cell receptor gene into the hematopoietic stem...


Word of the Day
barratry
  • The offense of persistently instigating lawsuits, typically groundless ones.
  • An unlawful breach of duty on the part of a ship's master or crew resulting in injury to the ship's owner.
  • Sale or purchase of positions in church or state.
This word ultimately comes from the Old French word 'barater,' to cheat.
Related